New shot before surgery could simplify breast cancer care in algeria
NCT ID NCT07166185
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 21 times
Summary
This study is testing whether a combination of two drugs given as a single shot under the skin (Phesgo) before surgery can completely destroy cancer in women with early-stage HER2-positive breast cancer. About 70 women in Algeria will receive the shot along with standard chemotherapy for about 18 weeks, then have surgery. The main goal is to see how many have no cancer left in the breast or nearby lymph nodes after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON METASTATIC HER2 POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medical oncology department - Anti Cancer Center of Blida
RECRUITINGBlida, 09000, Algeria
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.